Characterization of Freezing Processes in Drug Substance Bottles by Ice Core Sampling.

Jörg Huwyler, Hanns-Christian Mahler, Sarah S Peláez, Pau Rubirola Vila, Andrea Allmendinger

Journal: AAPS PharmSciTech 2024;25(5):102

PMID: 38714592

Abstract

Freezing of biological drug substance (DS) is a critical unit operation that may impact product quality, potentially leading to protein aggregation and sub-visible particle formation. Cryo-concentration has been identified as a critical parameter to impact protein stability during freezing and should therefore be minimized. The macroscopic cryo-concentration, in the following only referred to as cryo-concentration, is majorly influenced by the freezing rate, which is in turn impacted by product independent process parameters such as the DS container, its size and fill level, and the freezing equipment. (At-scale) process characterization studies are crucial to understand and optimize freezing processes. However, evaluating cryo-concentration requires sampling of the frozen bulk, which is typically performed by cutting the ice block into pieces for subsequent analysis. Also, the large amount of product requirement for these studies is a major limitation. In this study, we report the development of a simple methodology for experimental characterization of frozen DS in bottles at relevant scale using a surrogate solution. The novel ice core sampling technique identifies the axial ice core in the center to be indicative for cryo-concentration, which was measured by osmolality, and concentrations of histidine and polysorbate 80 (PS80), whereas osmolality revealed to be a sensitive read-out. Finally, we exemplify the suitability of the method to study cryo-concentration in DS bottles by comparing cryo-concentrations from different freezing protocols (-80°C vs -40°C). Prolonged stress times during freezing correlated to a higher extent of cryo-concentration quantified by osmolality in the axial center of a 2 L DS bottle.

© 2024. The Author(s).

Address: ten23 health AG, Mattenstrasse 22, 4058, Basel, Switzerland.; Institute of Pharmaceutical Technology, Goethe University Frankfurt, Max-Von-Laue-Strasse 9, 60438, Frankfurt am Main, Germany.; ten23 health AG, Mattenstrasse 22, 4058, Basel, Switzerland.; Institute of Pharmaceutical Technology, Goethe University Frankfurt, Max-Von-Laue-Strasse 9, 60438, Frankfurt am Main, Germany.; Department Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.; ten23 health AG, Mattenstrasse 22, 4058, Basel, Switzerland.; Department Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.; ten23 health AG, Mattenstrasse 22, 4058, Basel, Switzerland. [email protected].; Institute of Pharmaceutical Sciences, Department of Pharmaceutics, University of Freiburg, Sonnenstr. 5, 79104, Freiburg, Germany. [email protected].

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.